Adam Muzikant - 21 Jun 2021 Form 4 Insider Report for Flexion Therapeutics Inc

Role
Chief Business Officer
Signature
/s/ Mark S. Levine, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
21 Jun 2021
Net transactions value
+$16,190
Form type
4
Filing time
28 Jun 2021, 18:13:33 UTC
Next filing
20 Jul 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FLXN Common Stock Award $16,190 +2,081 +2% $7.78 105,536 21 Jun 2021 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This Form 4 is being filed voluntarily to report the acquisition of 2,081 shares by the Reporting Person on June 21, 2021, pursuant to the Issuer's Employee Stock Purchase Plan.